Nomifensine in geriatric inpatients: a placebo-controlled study. 1984

W Jansen, and K Siegfried

In a double-blind randomized group design, nomifensine (100 mg single daily dose) was compared to placebo in 100 geriatric inpatients (average age = 75 years). Patients in each group were categorized as depressed (Feighner criteria for primary depressive disorder and Hamilton Depression Rating Scale scores greater than or equal to 18) or non-depressed (no psychopathologic disorders and HDRS scores less than or equal to 7). Outcome measures included the HDRS and various tests of cognitive function. The nomifensine-treated depressed patients showed significant improvement over the placebo depressed patients early in and throughout treatment. Depressed patients also showed significant improvement on several cognitive tests with nomifensine treatment. Nomifensine was well tolerated in both depressed and nondepressed patients.

UI MeSH Term Description Entries
D007546 Isoquinolines A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed)
D008297 Male Males
D009627 Nomifensine An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266) Hoe-984,Linamiphen,Merital,Nomifensin,Nomifensine Maleate,Nomifensine Maleate (1:1),Hoe 984,Hoe984,Maleate, Nomifensine
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D011581 Psychological Tests Standardized tests designed to measure abilities (as in intelligence, aptitude, and achievement tests) or to evaluate personality traits. Parenting Stress Index,Trier Social Stress Test,Trier Stress Test,Psychologic Tests,Psychological Test,Test, Psychological,Tests, Psychological,Index, Parenting Stress,Psychologic Test,Stress Index, Parenting,Stress Test, Trier,Test, Psychologic,Test, Trier Stress,Trier Stress Tests
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003072 Cognition Disorders Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment. Overinclusion,Disorder, Cognition,Disorders, Cognition
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions

Related Publications

W Jansen, and K Siegfried
April 1984, The Journal of clinical psychiatry,
W Jansen, and K Siegfried
January 2002, European journal of clinical pharmacology,
W Jansen, and K Siegfried
January 1984, Neuropsychobiology,
W Jansen, and K Siegfried
August 2019, International journal of clinical pharmacy,
W Jansen, and K Siegfried
April 1984, The Journal of clinical psychiatry,
W Jansen, and K Siegfried
April 1984, The Journal of clinical psychiatry,
W Jansen, and K Siegfried
January 1980, Proceedings of the annual meeting of the American Psychopathological Association,
W Jansen, and K Siegfried
January 1977, British journal of clinical pharmacology,
Copied contents to your clipboard!